Burns Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | Skingenix, RenovaCare, CUTISS AG, Argle Therapeutics, Medline Industries

The Key Burns Companies in the market include - Kerecis, Mallinckrodt Pharmaceuticals, Skingenix, RenovaCare, CUTISS AG, Argle Therapeutics, Medline Industries, Amryt Pharma, MediWound Ltd, MediWound Ltd, Cumberland Pharmaceuticals, Pfizer, Kuros Biosurgery AG, Bayer, and others.

DelveInsight's "Burns Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Burns, historical and forecasted epidemiology as well as the Burns market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Burns market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Burns Market Forecast [https://www.delveinsight.com/sample-request/burns-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Burns Market Report:

*
The Burns market size was valued approximately ~USD 1,577 Million 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In August 2024, MediWound Ltd. (Nasdaq: MDWD), a leading company in enzymatic therapeutics for tissue repair, announced that the U.S. Food and Drug Administration (FDA) has granted approval for a pediatric indication of NexoBrid Registered (anacaulase-bcdb). This approval permits its use for eschar removal in pediatric patients, from newborns to 18 years old, with deep partial- and full-thickness thermal burns.

*
In 2023, the market size in the EU4 and the UK was approximately USD 501 million, representing about 32% of the total market size in the 7MM.

*
Within the EU4 and the UK, the United Kingdom had the largest market size at around USD 165 million, followed by France at approximately USD 104 million and Germany at USD 87 million. These figures are expected to change during the forecast period.

*
In 2023, the burns market size in Japan represented about 14% of the total market size in the 7MM, with anticipated changes by 2034.

*
In 2023, there were approximately 5.4 million reported incident cases of burn injuries, with about 1.8 million requiring medical treatment across the 7MM. This number is projected to rise by 2034 due to an increase in industrial accidents, household incidents, and natural disasters.

*
The number of hospitalized burn cases in the 7MM market is anticipated to grow at a compound annual growth rate (CAGR) of 0.54% during the study period from 2020 to 2034.

*
In 2023, the US reported the highest number of burn injuries requiring medical treatment, with around 671,128 cases, followed by Japan with approximately 329,241 cases and the UK with 280,817 cases.

*
Among the EU4 and the UK, the UK had the highest number of burn patients needing medical treatment, with approximately 280,817 cases, followed by France and Spain with around 204,506 and 145,510 cases.

*
Key Burns Companies: Kerecis, Mallinckrodt Pharmaceuticals, Skingenix, RenovaCare, CUTISS AG, Argle Therapeutics, Medline Industries, Amryt Pharma, MediWound Ltd, MediWound Ltd, Cumberland Pharmaceuticals, Pfizer, Kuros Biosurgery AG, Bayer, and others

*
Key Burns Therapies: Kerecis Omega3, StrataGraft, MW-III, CellMist System, EHSG-KF (denovoSkin), AGLE-102, PluroGel, Oleogel-S10, DGD, NexoBrid, Caldolor, linezolid, I-020502, Ciprofloxacin (BAYO9867), and others

*
The Burns epidemiology based on gender analyzed that in the 7MM males contributes to higher incident cases as compared to females

*
The Burns market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Burns pipeline products will significantly revolutionize the Burns market dynamics.

Burns Overview

Burns are injuries to the skin or other tissues caused by exposure to heat, electricity, chemicals, or radiation. They can range from mild to severe and are classified based on their depth and extent

Get a Free sample for the Burns Market Report:

https://www.delveinsight.com/report-store/burns-market [https://www.delveinsight.com/report-store/burns-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Burns Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Burns Epidemiology Segmentation:

The Burns market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Burns

*
Prevalent Cases of Burns by severity

*
Gender-specific Prevalence of Burns

*
Diagnosed Cases of Episodic and Chronic Burns

Download the report to understand which factors are driving Burns epidemiology trends @ Burns Epidemiology Forecast [https://www.delveinsight.com/sample-request/burns-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Burns Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Burns market or expected to get launched during the study period. The analysis covers Burns market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Burns Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Burns Therapies and Key Companies

*
Kerecis Omega3: Kerecis

*
StrataGraft: Mallinckrodt Pharmaceuticals

*
MW-III: Skingenix

*
CellMist System: RenovaCare

*
EHSG-KF (denovoSkin): CUTISS AG

*
AGLE-102: Argle Therapeutics

*
PluroGel: Medline Industries

*
Oleogel-S10: Amryt Pharma

*
DGD: MediWound Ltd

*
NexoBrid: MediWound Ltd

*
Caldolor: Cumberland Pharmaceuticals

*
linezolid: Pfizer

*
I-020502: Kuros Biosurgery AG

*
Ciprofloxacin (BAYO9867): Bayer

Discover more about therapies set to grab major Burns market share @ Burns Treatment Market [https://www.delveinsight.com/sample-request/burns-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Burns Market Drivers

*
Ongoing researches to develop treatment for severely burned patients Abundance of approved therapies

*
Rising incidence

*
Advancements in burn care treatments and products

Burns Market Barriers

*
Complications associated with available therapies

*
Lack of cost effective treatment

*
Lack of robust clinical pipeline

*
Limited awareness on burn care

Scope of the Burns Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Burns Companies: Kerecis, Mallinckrodt Pharmaceuticals, Skingenix, RenovaCare, CUTISS AG, Argle Therapeutics, Medline Industries, Amryt Pharma, MediWound Ltd, MediWound Ltd, Cumberland Pharmaceuticals, Pfizer, Kuros Biosurgery AG, Bayer, and others

*
Key Burns Therapies: Kerecis Omega3, StrataGraft, MW-III, CellMist System, EHSG-KF (denovoSkin), AGLE-102, PluroGel, Oleogel-S10, DGD, NexoBrid, Caldolor, linezolid, I-020502, Ciprofloxacin (BAYO9867), and others

*
Burns Therapeutic Assessment: Burns current marketed and Burns emerging therapies

*
Burns Market Dynamics: Burns market drivers and Burns market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Burns Unmet Needs, KOL's views, Analyst's views, Burns Market Access and Reimbursement

To know more about Burns companies working in the treatment market, visit @ Burns Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/burns-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Burns Market Report Introduction

2. Executive Summary for Burns

3. SWOT analysis of Burns

4. Burns Patient Share (%) Overview at a Glance

5. Burns Market Overview at a Glance

6. Burns Disease Background and Overview

7. Burns Epidemiology and Patient Population

8. Country-Specific Patient Population of Burns

9. Burns Current Treatment and Medical Practices

10. Burns Unmet Needs

11. Burns Emerging Therapies

12. Burns Market Outlook

13. Country-Wise Burns Market Analysis (2020-2034)

14. Burns Market Access and Reimbursement of Therapies

15. Burns Market Drivers

16. Burns Market Barriers

17. Burns Appendix

18. Burns Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=burns-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20242034-states-delveinsight-skingenix-renovacare-cutiss-ag-argle-therapeutics-medline-industries]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.